Meta-analysis: Association between MTHFR c.677C>T polymorphism and cancer in the Turkish population

Volume: 51 Number: 4 December 1, 2012
  • Çetintaş V B
  • Avcı Ç B
  • Süslüer S Y
  • Eroğlu Z
  • Gündüz C
EN TR

Meta-analysis: Association between MTHFR c.677C>T polymorphism and cancer in the Turkish population

Abstract

Global DNA hypomethylation associates with hyperhomocysteinemia, MTHFR c.677C>T homozygosity and the development of cancer. Aim: The aim of this study was to investigate the relationship of the MTHFR c.677C>T polymorphism with the risk of cancer in the Turkish population via meta-analysis. Materials and Methods: Studies were identified by searching electronic literature, focusing on the key words; Turkish population, MTHFR C677T and the risk of cancer. All data were analyzed using STATA software. Odds ratio (OR) and 95% confidence interval (Cl) values were calculated using the Mantel-Haentzel statistic according to fixed-effect model. Results: Odds ratio values for Recessive (CC+CT vs TT), Homozygous (CC vs TT) and Dominant (CC vs CT+TT) genetic models were calculated as 1.24 (95% CI: 1.013-1.524), 1.14 (95% CI: 0.93-1.41) and 0.97 (95% CI: 0.869-1.090), respectively. The risk of cancer increased significantly in the TT genotype (p=0.043). Conclusion: Our results support the finding that MTHFR c.677C>T polymorphism is a potential biomarker for cancer risk in the Turkish population.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Çetintaş V B

Avcı Ç B

Süslüer S Y

Eroğlu Z

Gündüz C

Publication Date

December 1, 2012

Submission Date

December 1, 2012

Acceptance Date

-

Published in Issue

Year 1970 Volume: 51 Number: 4

Vancouver
1.Çetintaş V B, Avcı Ç B, Süslüer S Y, Eroğlu Z, Gündüz C. Meta-analiz: Türk Toplumunda MTHFR c.677C>T polimorfizmi ve kanser ilişkisi. EJM [Internet]. 2012 Dec. 1;51(4):221-8. Available from: https://izlik.org/JA65WE44HX

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.